INBRAIN Neuroelectronics is a technology company.
INBRAIN Neuroelectronics has raised $71.0M across 3 funding rounds.
Key people at INBRAIN Neuroelectronics.
INBRAIN Neuroelectronics has raised $71.0M in total across 3 funding rounds.
INBRAIN Neuroelectronics has raised $71.0M in total across 3 funding rounds.
INBRAIN Neuroelectronics's investors include Asabys Partners, Earthshots Collective, Karista, Vsquared Ventures, Wellington Partners.
Key people at INBRAIN Neuroelectronics.
INBRAIN Neuroelectronics is a Barcelona-based medical device company developing graphene-based neural interfaces and brain-computer interfaces (BCIs) for personalized therapies targeting neurological disorders like Parkinson's, epilepsy, and others.[1][2][3][4] Their end-to-end platform combines skin-like, bi-directional high-resolution implants (up to 1024 contacts), implantable neural processors with wireless rechargeable batteries, and AI-powered data analytics to enable real-time neural decoding and closed-loop modulation, restoring function or mobility while minimizing invasiveness.[3][4][5] Serving patients and clinicians, INBRAIN addresses the "neural challenge"—affecting a significant portion of the world population, the leading cause of disability and second cause of mortality, with costs exceeding cancer and cardiovascular diseases combined—by outperforming metal-based alternatives like platinum with graphene's superior signal resolution and precision.[1][3][4] The platform has FDA Breakthrough Device Designation for Parkinson's, signaling strong growth momentum through partnerships like Merck KGaA and recognition as outperforming competitors like Neuralink.[3]
INBRAIN Neuroelectronics was founded in 2019 (with some sources noting 2020) as a spin-off from the Graphene Flagship—a €1B EU program highlighted by the Nobel Prize for Graphene—and partners including the Catalan Institute of Nanoscience and Nanotechnology (ICN2), ICREA, and the University of Manchester.[1][2][4] The idea emerged from groundbreaking graphene research by ICN2 and Graphene Flagship teams, enabling high-fidelity neural signal decoding and modulation for smart, personalized brain implants to treat conditions like epilepsy and Parkinson's.[2][4] Key figures include CEO Carolina Aguilar (former Medtronic Global Director), Graphene Flagship experts Jose Garrido, Kostas Kostarelos, and Anton Guimera, plus neurotechnology veterans from Philips, Medtronic, and startups.[4] Early traction came from leveraging this Nobel-winning material for less invasive devices, quickly advancing to FDA designation and high-profile collaborations.[3][4]
INBRAIN stands out in neuroelectronics through graphene's unique properties, delivering unmatched performance over traditional metal electrodes:
INBRAIN rides the brain-computer interface (BCI) and bioelectronics wave, harnessing graphene—a 2010 Nobel-winning material—to pioneer precision neuromodulation amid rising demand for treatments of neural disorders impacting billions.[1][3][4] Timing is ideal post-Graphene Flagship investments and amid BCI hype from players like Neuralink, but INBRAIN's minimally invasive, high-resolution approach addresses limitations of invasive, low-res generics, positioning it at the frontier of precision medicine akin to genomics' impact.[3][4][5] Market forces favor it: escalating neural disease burdens (WHO data), regulatory nods like FDA Breakthrough, and partnerships (e.g., Merck KGaA for next-gen bioelectronics).[3] By advancing graphene neural tech from EU research ecosystems, INBRAIN influences the shift to scalable, AI-driven neurotherapeutics, democratizing high-fidelity BCIs beyond experimental stages.[1][4]
INBRAIN is poised to lead graphene-powered neurotherapeutics, with clinical trials, expanded FDA approvals, and commercialization of its BCI platform likely next, building on Parkinson's designation and Merck collaboration.[3] Trends like AI integration in medtech, rising bioelectronics funding, and global neural health crises will propel growth, potentially evolving INBRAIN into a dominant player in personalized BCIs—outpacing metal-based rivals and redefining treatments for epilepsy, Parkinson's, and beyond.[1][3][4] As a Graphene Flagship heir, its influence could spark an ecosystem of high-res neural interfaces, "lighting up the path to a better neural future" by solving the neural challenge at scale.[3]
INBRAIN Neuroelectronics has raised $71.0M across 3 funding rounds. Most recently, it raised $50.0M Series B in October 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2024 | $50.0M Series B | Asabys Partners, Earthshots Collective, Karista, Vsquared Ventures, Wellington Partners | |
| Mar 1, 2021 | $20.0M Series A | Asabys Partners, Earthshots Collective, Karista, Vsquared Ventures, Wellington Partners | |
| Jun 1, 2020 | $1.0M Seed | Asabys Partners, Wellington Partners |
